Literature DB >> 1281187

Murine B7 antigen provides a sufficient costimulatory signal for antigen-specific and MHC-restricted T cell activation.

F Galvin1, G J Freeman, Z Razi-Wolf, W Hall, B Benacerraf, L Nadler, H Reiser.   

Abstract

We have previously shown that the murine B7 (mB7) molecule, when expressed in Chinese hamster ovary cells in stable fashion, can costimulate with anti-CD3 mAb or Con A to induce T cell activation. We have now derived, by gene transfection, Chinese hamster ovary cell lines that express the I-Ad molecule, either alone or in context with mB7. We have analyzed these transfectants for their capacity to present Ag to murine CD4+ T lymphocytes. I-Ad/mB7-double transfectants were able to stimulate mixed lymphocyte reactions and to present peptide Ag to specific T cells. Chinese hamster ovary cells that expressed only the I-Ad molecule were not able to stimulate T cell proliferation in these systems. Thus, the mB7 protein is a sufficient costimulatory molecule for the physiologic, Ag-dependent/MHC-restricted activation of murine CD4+ T cells. Stimulation of T cell bulk cultures resulted predominantly in the production of IL-2 and not of IL-4. The costimulatory activity of mB7 is not, however, restricted to the IL-2-secreting subset. We have identified one IL-4-secreting T cell clone, CDC35, which is responsive to mB7 triggering. Finally, we present experiments that suggest that mB7 and peptide/MHC complexes need to be expressed on the same cell for optimal induction of T cell activation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1281187

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

1.  B7-dependent T-cell costimulation in mice lacking CD28 and CTLA4.

Authors:  D A Mandelbrot; M A Oosterwegel; K Shimizu; A Yamada; G J Freeman; R N Mitchell; M H Sayegh; A H Sharpe
Journal:  J Clin Invest       Date:  2001-04       Impact factor: 14.808

2.  Tolerogenicity of resting and activated B cells.

Authors:  K M Gilbert; W O Weigle
Journal:  J Exp Med       Date:  1994-01-01       Impact factor: 14.307

3.  The defective antigen-presenting activity of murine fetal macrophage cell lines.

Authors:  H Khalili; R Deshpande; M Y Chang
Journal:  Immunology       Date:  1997-12       Impact factor: 7.397

4.  Enhancement of antigen-presenting ability of B lymphoma cells by partial inhibition of protein synthesis through inducing B7-1 expression.

Authors:  T Aoi; H Nakano; Y Tanaka; T Kakiuchi
Journal:  Immunology       Date:  1997-06       Impact factor: 7.397

5.  CD28-B7 costimulatory blockade by CTLA4Ig delays the development of retrovirus-induced murine AIDS.

Authors:  L de Leval; S Colombi; S Debrus; M A Demoitié; R Greimers; P Linsley; M Moutschen; J Boniver
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

6.  Transfected Drosophila cells as a probe for defining the minimal requirements for stimulating unprimed CD8+ T cells.

Authors:  Z Cai; A Brunmark; M R Jackson; D Loh; P A Peterson; J Sprent
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

7.  Enhancement of B7-1 (CD80) expression on B-lymphoma cells by irradiation.

Authors:  A Seo; F Ishikawa; H Nakano; H Nakazaki; K Kobayashi; T Kakiuchi
Journal:  Immunology       Date:  1999-04       Impact factor: 7.397

8.  Construction, purification, and functional incorporation on tumor cells of glycolipid-anchored human B7-1 (CD80).

Authors:  R S McHugh; S N Ahmed; Y C Wang; K W Sell; P Selvaraj
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

9.  Reduced lysis by CD8+ cytotoxic T cells in mixed lymphocyte reactions induced via CD4+ T cells exposed to chemically modified antigen presenting cells.

Authors:  L Corlett; D H Davies
Journal:  Immunology       Date:  1995-03       Impact factor: 7.397

10.  Evidence for an additional ligand, distinct from B7, for the CTLA-4 receptor.

Authors:  Z Razi-Wolf; F Galvin; G Gray; H Reiser
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.